Toth Financial Advisory Corp Reduces Position in Abbott Laboratories $ABT

Key Points

• Toth Financial Advisory Corp. reduced its Abbott Laboratories position by 18.2% in the second quarter, selling 20,574 shares and retaining 92,196 shares valued at approximately $8.37 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Analysts remain broadly bullish, with Abbott receiving a consensus “Moderate Buy” rating and an average price target of $119.50; several firms recently raised their targets to between $118 and $134.
• Abbott exceeded quarterly earnings and revenue expectations, reporting $1.31 in EPS and $12.59 billion in revenue, while maintaining a quarterly dividend of $0.63, equivalent to a 2.3% annualized yield.

Toth Financial Advisory Corp trimmed its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 18.2% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 92,196 shares of the healthcare product maker's stock after selling 20,574 shares during the quarter. Toth Financial Advisory Corp's holdings in Abbott Laboratories were worth $8,366,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of ABT. J. Stern & Co. LLP lifted its position in Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Norges Bank purchased a new stake in Abbott Laboratories during the 4th quarter valued at $2,938,892,000. Bank of America Corp DE bought a new position in shares of Abbott Laboratories during the 2nd quarter valued at $1,603,607,000. Legal & General Group Plc purchased a new position in shares of Abbott Laboratories in the 2nd quarter worth $1,082,524,000. Finally, Flossbach Von Storch SE purchased a new position in shares of Abbott Laboratories in the 2nd quarter worth $902,938,000. Institutional investors own 75.18% of the company's stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Weiss Ratings raised Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 6th. Piper Sandler reaffirmed an "overweight" rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. JPMorgan Chase & Co. raised their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a report on Friday, July 17th. BTIG Research boosted their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research report on Friday, July 17th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $119.50.

Abbott Laboratories Trading Down 0.5%

Shares of NYSE:ABT opened at $108.29 on Friday. The stock has a 50 day moving average of $104.43 and a 200 day moving average of $100.12. The company has a market cap of $187.38 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.02 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm's revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories's dividend payout ratio is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source